Molecular monitoring in chronic myeloid leukemia: Response to tyrosine kinase inhibitors and prognostic implications

Elias Jabbour, Jorge E. Cortes, Hagop M. Kantarjian

Research output: Contribution to journalReview article

Abstract

The majority of patients with chronic phase (CP) chronic myeloid leukemia (CML) who are treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve cytogenetic disease remission (ie, Philadelphia chromosome-positive cells undetectable by cytogenetic evaluation). However, more sensitive methods are required for monitoring residual disease (ie, molecular monitoring of BCR-ABL transcript levels). It is generally accepted that molecular responses have prognostic significance. Patients with CP CML who achieve early molecular responses are more likely to achieve durable cytogenetic responses and are less likely to experience disease progression. Rising BCR-ABL transcript levels also indicate loss of response, often as a consequence of developing BCR-ABL mutations. However, some studies have suggested that patients who achieve complete cytogenetic disease remission may not derive an additional prognostic benefit from achieving a major molecular response. Practical issues also exist for molecular monitoring with respect to restricted access and variability in methodologies and data reporting. Although molecular monitoring has a clear role in assessing residual disease and determining the risk of disease progression in patients with CMP, the importance of cytogenetic monitoring should not be ignored.

Original languageEnglish (US)
Pages (from-to)2112-2118
Number of pages7
JournalCancer
Volume112
Issue number10
DOIs
StatePublished - May 15 2008
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Protein-Tyrosine Kinases
Leukemia, Myeloid, Chronic Phase
Disease Progression
bcr-abl Fusion Proteins
Cytidine Monophosphate
Philadelphia Chromosome
Research Design
Mutation

Keywords

  • Chronic myeloid leukemia
  • Cytogenetic analysis
  • Polymerase chain reaction
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Molecular monitoring in chronic myeloid leukemia : Response to tyrosine kinase inhibitors and prognostic implications. / Jabbour, Elias; Cortes, Jorge E.; Kantarjian, Hagop M.

In: Cancer, Vol. 112, No. 10, 15.05.2008, p. 2112-2118.

Research output: Contribution to journalReview article

@article{6d879170cd39482d9d88845b8bc45b77,
title = "Molecular monitoring in chronic myeloid leukemia: Response to tyrosine kinase inhibitors and prognostic implications",
abstract = "The majority of patients with chronic phase (CP) chronic myeloid leukemia (CML) who are treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve cytogenetic disease remission (ie, Philadelphia chromosome-positive cells undetectable by cytogenetic evaluation). However, more sensitive methods are required for monitoring residual disease (ie, molecular monitoring of BCR-ABL transcript levels). It is generally accepted that molecular responses have prognostic significance. Patients with CP CML who achieve early molecular responses are more likely to achieve durable cytogenetic responses and are less likely to experience disease progression. Rising BCR-ABL transcript levels also indicate loss of response, often as a consequence of developing BCR-ABL mutations. However, some studies have suggested that patients who achieve complete cytogenetic disease remission may not derive an additional prognostic benefit from achieving a major molecular response. Practical issues also exist for molecular monitoring with respect to restricted access and variability in methodologies and data reporting. Although molecular monitoring has a clear role in assessing residual disease and determining the risk of disease progression in patients with CMP, the importance of cytogenetic monitoring should not be ignored.",
keywords = "Chronic myeloid leukemia, Cytogenetic analysis, Polymerase chain reaction, Tyrosine kinase inhibitors",
author = "Elias Jabbour and Cortes, {Jorge E.} and Kantarjian, {Hagop M.}",
year = "2008",
month = "5",
day = "15",
doi = "10.1002/cncr.23427",
language = "English (US)",
volume = "112",
pages = "2112--2118",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Molecular monitoring in chronic myeloid leukemia

T2 - Response to tyrosine kinase inhibitors and prognostic implications

AU - Jabbour, Elias

AU - Cortes, Jorge E.

AU - Kantarjian, Hagop M.

PY - 2008/5/15

Y1 - 2008/5/15

N2 - The majority of patients with chronic phase (CP) chronic myeloid leukemia (CML) who are treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve cytogenetic disease remission (ie, Philadelphia chromosome-positive cells undetectable by cytogenetic evaluation). However, more sensitive methods are required for monitoring residual disease (ie, molecular monitoring of BCR-ABL transcript levels). It is generally accepted that molecular responses have prognostic significance. Patients with CP CML who achieve early molecular responses are more likely to achieve durable cytogenetic responses and are less likely to experience disease progression. Rising BCR-ABL transcript levels also indicate loss of response, often as a consequence of developing BCR-ABL mutations. However, some studies have suggested that patients who achieve complete cytogenetic disease remission may not derive an additional prognostic benefit from achieving a major molecular response. Practical issues also exist for molecular monitoring with respect to restricted access and variability in methodologies and data reporting. Although molecular monitoring has a clear role in assessing residual disease and determining the risk of disease progression in patients with CMP, the importance of cytogenetic monitoring should not be ignored.

AB - The majority of patients with chronic phase (CP) chronic myeloid leukemia (CML) who are treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve cytogenetic disease remission (ie, Philadelphia chromosome-positive cells undetectable by cytogenetic evaluation). However, more sensitive methods are required for monitoring residual disease (ie, molecular monitoring of BCR-ABL transcript levels). It is generally accepted that molecular responses have prognostic significance. Patients with CP CML who achieve early molecular responses are more likely to achieve durable cytogenetic responses and are less likely to experience disease progression. Rising BCR-ABL transcript levels also indicate loss of response, often as a consequence of developing BCR-ABL mutations. However, some studies have suggested that patients who achieve complete cytogenetic disease remission may not derive an additional prognostic benefit from achieving a major molecular response. Practical issues also exist for molecular monitoring with respect to restricted access and variability in methodologies and data reporting. Although molecular monitoring has a clear role in assessing residual disease and determining the risk of disease progression in patients with CMP, the importance of cytogenetic monitoring should not be ignored.

KW - Chronic myeloid leukemia

KW - Cytogenetic analysis

KW - Polymerase chain reaction

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=43049104149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049104149&partnerID=8YFLogxK

U2 - 10.1002/cncr.23427

DO - 10.1002/cncr.23427

M3 - Review article

C2 - 18348294

AN - SCOPUS:43049104149

VL - 112

SP - 2112

EP - 2118

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -